Physician profile
Robert O Johnson
NPI 1396263950
$3,978.51
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,609 · 2023: $1,482 · 2024: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,270.17 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.47 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $434.46 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $398.94 | 2022-2023 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $306.93 | 2022-2024 | |
| Janssen Biotech, INC. | $291.34 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $241.39 | 2022-2024 | Dupixent |
| Lilly USA, LLC | $182.97 | 2022-2024 | Taltz, Olumiant, Mounjaro |
| Amgen INC. | $181.81 | 2022-2024 | Otezla |
| Genzyme Corporation | $170.47 | 2022-2024 | |
| Leo Pharma INC. | $134.85 | 2022-2023 | Adbry |
| Novartis Pharmaceuticals Corporation | $95.44 | 2022-2024 | |
| Almirall LLC | $78.08 | 2022-2023 | Klisyri |
| Biofrontera INC. | $63.14 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Galderma Laboratories, L.P. | $62.64 | 2023-2024 | Aklief |
| Arcutis Biotherapeutics, INC. | $39.34 | 2023-2024 | Zoryve |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Epi Health, LLC | $38.06 | 2022 | |
| Mayne Pharma Commercial LLC | $35.02 | 2023 | |
| Journey Medical Corporation | $32.23 | 2022-2023 | |
| Ucb, INC. | $31.99 | 2024 | Bimzelx |
| Paratek Pharmaceuticals, INC. | $31.15 | 2023 | Nuzyra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $24.57 | 2023 | Arazlo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.12 | 2024 | |
| Incyte Corporation | $17.66 | 2024 | Opzelura |
| Dermavant Sciences, INC. | $17.44 | 2023 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.